Brokerages Set ProQR Therapeutics N.V. (NASDAQ:PRQR) Target Price at $8.00

ProQR Therapeutics N.V. (NASDAQ:PRQR) has earned a consensus rating of “Buy” from the eight analysts that are covering the stock, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $8.00.

Several research analysts have issued reports on PRQR shares. Cantor Fitzgerald restated an “overweight” rating and issued a $8.00 price target on shares of ProQR Therapeutics in a research report on Friday, June 27th. Evercore ISI reiterated an “outperform” rating on shares of ProQR Therapeutics in a research report on Friday, July 11th. Oppenheimer lowered their price objective on shares of ProQR Therapeutics from $15.00 to $9.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 13th. Finally, JMP Securities reiterated a “market outperform” rating and set a $8.00 price objective on shares of ProQR Therapeutics in a research report on Friday, June 27th.

Institutional Investors Weigh In On ProQR Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Bank of America Corp DE lifted its stake in shares of ProQR Therapeutics by 11.8% in the 4th quarter. Bank of America Corp DE now owns 81,784 shares of the biopharmaceutical company’s stock valued at $217,000 after purchasing an additional 8,621 shares during the last quarter. Jane Street Group LLC acquired a new stake in shares of ProQR Therapeutics in the 4th quarter valued at $30,000. Squarepoint Ops LLC lifted its stake in shares of ProQR Therapeutics by 16.3% in the 4th quarter. Squarepoint Ops LLC now owns 83,114 shares of the biopharmaceutical company’s stock valued at $220,000 after purchasing an additional 11,623 shares during the last quarter. Invesco Ltd. acquired a new stake in shares of ProQR Therapeutics in the 4th quarter valued at $32,000. Finally, OneDigital Investment Advisors LLC lifted its stake in shares of ProQR Therapeutics by 45.5% in the 1st quarter. OneDigital Investment Advisors LLC now owns 40,000 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 12,500 shares during the last quarter. Institutional investors and hedge funds own 32.65% of the company’s stock.

ProQR Therapeutics Stock Performance

ProQR Therapeutics stock opened at $2.23 on Friday. The firm has a market cap of $234.62 million, a price-to-earnings ratio of -6.37 and a beta of 0.36. ProQR Therapeutics has a 1 year low of $1.07 and a 1 year high of $4.62. The firm’s 50 day moving average price is $2.00 and its two-hundred day moving average price is $1.89.

ProQR Therapeutics (NASDAQ:PRQR) last posted its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.02). The business had revenue of $4.89 million during the quarter, compared to analyst estimates of $4.90 million. ProQR Therapeutics had a negative return on equity of 53.49% and a negative net margin of 157.04%. As a group, equities analysts predict that ProQR Therapeutics will post -0.31 EPS for the current fiscal year.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).